These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 21789337)

  • 1. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
    Olesen JB; Lip GY; Lindhardsen J; Lane DA; Ahlehoff O; Hansen ML; Raunsø J; Tolstrup JS; Hansen PR; Gislason GH; Torp-Pedersen C
    Thromb Haemost; 2011 Oct; 106(4):739-49. PubMed ID: 21789337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
    Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.
    Olesen JB; Lip GY; Lane DA; Køber L; Hansen ML; Karasoy D; Hansen CM; Gislason GH; Torp-Pedersen C
    Am J Med; 2012 Aug; 125(8):826.e13-23. PubMed ID: 22579139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry.
    Watanabe E; Yamamoto M; Kodama I; Inoue H; Atarashi H; Okumura K; Yamashita T; Lip GY; Kodani E; Okuyama Y; Chishaki A; Kiyono K; Origasa H;
    Int J Cardiol; 2016 Jun; 212():311-7. PubMed ID: 27057949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.
    Poli D; Antonucci E; Testa S; Tosetto A; Ageno W; Palareti G;
    Circulation; 2011 Aug; 124(7):824-9. PubMed ID: 21810658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study.
    Lamberts M; Lip GY; Ruwald MH; Hansen ML; Özcan C; Kristensen SL; Køber L; Torp-Pedersen C; Gislason GH
    J Am Coll Cardiol; 2014 Jun; 63(24):2689-98. PubMed ID: 24794118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL; Hwang JM; Moser LR
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation patients do not benefit from acetylsalicylic acid.
    Själander S; Själander A; Svensson PJ; Friberg L
    Europace; 2014 May; 16(5):631-8. PubMed ID: 24158253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Lamberts M; Olesen JB; Ruwald MH; Hansen CM; Karasoy D; Kristensen SL; Køber L; Torp-Pedersen C; Gislason GH; Hansen ML
    Circulation; 2012 Sep; 126(10):1185-93. PubMed ID: 22869839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.